Immunohistochemical staining with EGFR mutation-specific antibodies: High specificity as a diagnostic marker for lung adenocarcinoma Journal Article
| Authors: | Wen, Y. H.; Brogi, E.; Hasanovic, A.; Ladanyi, M.; Soslow, R. A.; Chitale, D.; Shia, J.; Moreira, A. L. |
| Article Title: | Immunohistochemical staining with EGFR mutation-specific antibodies: High specificity as a diagnostic marker for lung adenocarcinoma |
| Abstract: | We previously demonstrated a high specificity of immunohistochemistry using epidermal growth factor receptor (EGFR) mutation-specific antibodies in lung adenocarcinoma and correlation with EGFR mutation analysis. In this study, we assessed EGFR mutation status by immunohistochemistry in a variety of extrapulmonary malignancies, especially those that frequently show EGFR overexpression. Tissue microarrays containing triplicate cores of breast carcinomas (n=300), colorectal carcinomas (n=65), pancreatic adenocarcinoma (n=145), and uterine carcinosarcoma or malignant mixed müllerian tumors (n=25) were included in the study. Tissue microarray of lung adenocarcinoma with known EGFR mutation status was used as reference. Immunohistochemistry was performed using antibodies specific for the E746-A750del and L858R mutations. In pulmonary adenocarcinoma, a staining intensity of 2+ or 3+ correlates with mutation status and is therefore considered as positive. Out of 300 breast carcinomas, 293 (98%) scored 0, 5 (2%) had 1+ staining, 2 (1%) were 2+ for the L858R antibody. All breast carcinomas scored 0 with the E746-A750 antibody. All the colorectal, pancreatic carcinomas and malignant mixed müllerian tumors were negative (0) for both antibodies. Molecular analysis of the breast carcinomas that scored 2+ for L858R showed no mutation. Our results show that EGFR mutation-specific antibodies could be an additional tool distinguishing primary versus metastatic carcinomas in the lung. False-positivity can be seen in breast carcinoma but is extremely rare (1%). © 2013 USCAP, Inc All rights reserved. |
| Keywords: | immunohistochemistry; adult; human tissue; aged; primary tumor; gene mutation; major clinical study; cancer staging; gene overexpression; epidermal growth factor receptor; mutational analysis; tumor marker; colorectal carcinoma; liver metastasis; lung metastasis; lung adenocarcinoma; breast carcinoma; cancer size; pancreas adenocarcinoma; tissue microarray; epidermal growth factor receptor antibody; uterus carcinoma; mixed mullerian tumor; molecular diagnosis; triple-negative breast cancer; mutation-specific antibody |
| Journal Title: | Modern Pathology |
| Volume: | 26 |
| Issue: | 9 |
| ISSN: | 0893-3952 |
| Publisher: | Nature Research |
| Date Published: | 2013-09-01 |
| Start Page: | 1197 |
| End Page: | 1203 |
| Language: | English |
| DOI: | 10.1038/modpathol.2013.53 |
| PROVIDER: | scopus |
| PUBMED: | 23599147 |
| PMCID: | PMC4159955 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 1 October 2013" - "CODEN: MODPE" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work